Lansoprazole
Product Images NDC 69336-107

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 69336-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sterling Knight Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (30 mg 30 Capsule Bottle Label)

Lansoprazole 30 mg delayed-release capsules label from Sterling Knight Pharmaceuticals LLC. The label shows product NDC 69336-107-30 and indicates each dark blue and pink capsule contains 30 mg of lansoprazole as enteric-coated pellets. The package contains 30 capsules. Storage instructions and a medication guide dispenser warning are also included.*

FDA Label Image

Chemical Structure (Lansoprazole 01)

Chemical structure of lansoprazole showing its molecular formula with ring structures including a benzimidazole and a substituted pyridine attached by a sulfoxide group.*

FDA Label Image

Figure 1 (Lansoprazole 02)

A line graph titled "Mean Severity of Day Heartburn By Study Day For Evaluable Patients" comparing placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily. The x-axis shows days from start of treatment (ranging from -5 to 60), and the y-axis shows mean severity of day heartburn on a scale from 0 (none) to 3 (severe). The graph illustrates a decline in heartburn severity over time for both lansoprazole doses compared to placebo.*

FDA Label Image

Figure 2 (Lansoprazole 03)

A line graph titled 'Mean Severity of Night Heartburn By Study Day For Evaluable Patients' comparing three groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD. The Y-axis shows mean severity levels from 0 (None) to 3 (Severe), and the X-axis shows days from start of treatment, ranging from 0 to 60 days. The graph illustrates decreasing heartburn severity over time for both lansoprazole doses compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.